Loading…
Lakefront Biotherapeutics NV is projected to rise to $36.53 by 2027, a +32% move from its current price of $27.73. LKFT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $27.33 | $27.74 | $28.16 | +0.05% |
| May 30 | $27.17 | $27.76 | $28.36 | +0.10% |
| May 31 | $27.06 | $27.77 | $28.51 | +0.15% |
| Jun 1 | $26.96 | $27.79 | $28.64 | +0.20% |
| Jun 2 | $26.88 | $27.80 | $28.75 | +0.25% |
| Jun 3 | $26.81 | $27.81 | $28.86 | +0.30% |
| Jun 4 | $26.74 | $27.83 | $28.96 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.74 | $27.83 | $28.96 | +0.35% |
| Week 2 | $26.40 | $27.93 | $29.54 | +0.70% |
| Week 3 | $26.15 | $28.02 | $30.03 | +1.06% |
| Week 4 | $25.97 | $28.12 | $30.45 | +1.41% |
| Week 5 | $25.82 | $28.22 | $30.85 | +1.77% |
| Week 6 | $25.69 | $28.32 | $31.22 | +2.13% |
| Week 7 | $25.58 | $28.42 | $31.58 | +2.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lakefront Biotherapeutics NV is a biotechnology company that develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Its pipeline comprises GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.
The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company focused on oncology and immunology with activities in the United States and Europe. It trades at $27.49 and has a market cap of $1.81B, ranking 2066 by market capitalization.
Current price and market position are complemented by a forward-looking forecast that shows near-term neutral activity in 2026 (min $26.61, avg $27.49, max $36.47; ROI 0%; sentiment NEUTRAL) and a bullish trajectory thereafter, with rising average values and substantial upside by 2050 (avg $163.50; max $267.55).
A major floor 9.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 5.6% above — a clean break opens room to run.
A major ceiling 24.9% above — clearing it would confirm fresh momentum.
Key LKFT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LKFT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.61 | Buy | $27.57 | Buy |
| MA 10 | $27.40 | Buy | $27.55 | Buy |
| MA 20 | $27.72 | Buy | $27.81 | Sell |
| MA 50 | $28.88 | Sell | $28.94 | Sell |
| MA 100 | $31.24 | Sell | $30.14 | Sell |
| MA 200 | $31.80 | Sell | $30.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.80 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 0.84 | Neutral |
| Williams %R (14) | -43.43 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | -3.01 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 56.57 | Neutral |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -0.56 | Sell |
| Ultimate (7,14,28) | 56.27 | Neutral |
| Momentum (10) | 0.40 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 27.83 | Sell |
| ADX (14) | 18.49 | Neutral |
| ATR (14) | 0.40 | Info |
The 30-day technical picture is neutral, with RSI14 at 40.
The stock is trading near key moving averages, with SMA50 at $29.06 and SMA200 at $31.85. Support sits at $26.61 and resistance at $29.28.
The thirty-day range is $24.75 to $30.54, indicating modest upside potential within a constrained near-term band. Annualized volatility is 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.61 | $27.73 | $36.71 | 0% | Neutral | |
| $29.84 | $36.53 | $46.80 | +32% | Bullish | |
| $32.89 | $41.00 | $53.90 | +48% | Bullish | |
| $31.73 | $40.15 | $53.88 | +45% | Bullish | |
| $33.71 | $43.22 | $59.04 | +56% | Bullish | |
| $35.88 | $46.56 | $64.58 | +68% | Bullish | |
| $39.18 | $51.41 | $72.32 | +85% | Bullish | |
| $46.12 | $61.15 | $87.12 | +121% | Bullish | |
| $48.03 | $64.32 | $92.72 | +132% | Bullish | |
| $49.77 | $67.27 | $98.05 | +143% | Bullish | |
| $71.63 | $100.96 | $154.15 | +264% | Bullish | |
| $108.58 | $164.12 | $268.54 | +492% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.61 | $27.73 | $32.42 | +0.00% |
| June 2026 | $24.16 | $28.19 | $33.52 | +1.65% |
| July 2026 | $24.74 | $29.03 | $34.84 | +2.97% |
| August 2026 | $24.42 | $28.78 | $34.80 | -0.84% |
| September 2026 | $24.03 | $28.42 | $34.57 | -1.24% |
| October 2026 | $24.57 | $29.16 | $35.66 | +2.60% |
| November 2026 | $25.03 | $29.79 | $36.61 | +2.16% |
| December 2026 | $24.91 | $29.74 | $36.71 | -0.17% |
Click any year to see its month-by-month LKFT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lakefront Biotherapeutics NV's 2026 outlook centres on $27.73, within a $26.61 to $36.71 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, LKFT could reach as high as $46.80, with a base case around $36.53 and support toward $29.84 — roughly +32% from $27.73. Buyers look set to stay in control over this stretch.
Expect LKFT to range from $32.89 to $53.90 through 2028. The $41.00 average target implies a +48% move from current prices. That is up +12% on the projected 2027 average. Momentum favours further upside here.
The LKFT price prediction for 2029 points to an average of $40.15 (low $31.73, high $53.88) — a potential gain of +45% on today's $27.73. Buyers look set to stay in control over this stretch.
In 2030, LKFT is projected to trade between $33.71 and $59.04, averaging $43.22 — a potential gain of +56% from today's $27.73. That is up +8% on the projected 2029 average. Momentum favours further upside here.
Lakefront Biotherapeutics NV's 2031 outlook centres on $46.56, within a $35.88 to $64.58 range. That is up +8% on the projected 2030 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, LKFT could reach as high as $72.32, with a base case around $51.41 and support toward $39.18 — roughly +85% from $27.73. Momentum favours further upside here.
Expect LKFT to range from $46.12 to $87.12 through 2033. The $61.15 average target implies a +121% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The LKFT price prediction for 2034 points to an average of $64.32 (low $48.03, high $92.72) — a potential gain of +132% on today's $27.73. Momentum favours further upside here.
In 2035, LKFT is projected to trade between $49.77 and $98.05, averaging $67.27 — a potential gain of +143% from today's $27.73. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Lakefront Biotherapeutics NV's 2040 outlook centres on $100.96, within a $71.63 to $154.15 range. That is up +50% on the projected 2035 average. That marks a +264% change versus current levels. Momentum favours further upside here.
By 2050, LKFT could reach as high as $268.54, with a base case around $164.12 and support toward $108.58 — roughly +492% from $27.73. Buyers look set to stay in control over this stretch.
Investing $1,000 in LKFT today (≈ 36.062027 LKFT) could be worth
$5,918.34
+$4,918.34 (+492%) by 2050 · US Dollar
Based on the average projected LKFT price of $164.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LKFTwould be worth at today's price.
$1,000 invested in LKFT on May 27, 2025 (≈ 34.518468 LKFT) would be worth
$957.2
-$42.8 (-4.3%) today · 0.96× · US Dollar
Based on a LKFT entry price of $28.97 vs. today's $27.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.4 | $1,012.04 | +1.2% |
| 1 month ago | $28.47 | $974.01 | -2.6% |
| 3 months ago | $33.49 | $828.01 | -17.2% |
| 6 months ago | $31.32 | $885.38 | -11.5% |
| 1 year ago | $28.97 | $957.2 | -4.3% |
| All time (5.0y) ago | $73.83 | $375.59 | -62.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LKFT forecast.
Our base-case forecast reaches $55.00 around 2033.
Implied market cap at $55.00: $3.62B
The multi-year forecast shows a bullish trajectory across the calendar years, with rising average prices and meaningful upside potential.
For 2030, the min is $33.62, the avg is $43.11 and the max is $58.90, with a 56.8% ROI and bullish sentiment.
In 2040, the min is $70.98, the avg is $100.05 and the max is $152.79, with a 264% ROI and bullish sentiment.
By 2050, the min is $108.17, the avg is $163.50 and the max is $267.55, with a 494.8% ROI and bullish sentiment.
These figures illustrate a rising trajectory through 2030, 2040 and 2050, but they are estimates and not guarantees.
Tap a question to reveal the answer.
Min $33.62, Avg $43.11, Max $58.90; ROI 56.8%; sentiment BULLISH.
Forecast shows bullish sentiment in 2027–2050 with rising averages and ROI up to 494.8% by 2050; these are estimates, not guarantees.
Yes—the forecast max by 2050 is $267.55, which exceeds $200.
Current price $27.49; Market cap $1.81B.
2040 max $152.79.
Lakefront Biotherapeutics NV Community Discussion
0Share your Lakefront Biotherapeutics NV price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.